GlobeNewswire by notified

Insider information - Clarification of expectations for 2023

Share

COMPANY ANNOUNCEMENT

        Odense, December 4th, 2023

Company Announcement no. 45 – 12.04.2023

Insider information - Clarification of expectations for 2023

Danish Aerospace Company A/S (DAC) has previously, for its 2023 Financial Year, announced an expected revenue in the range of DKK 24-26 million and a positive operating profit (EBITDA) in the range of DKK 3-4 million.

In connection with the 2023 Interim report, DAC briefed the market on expectations in the lower end compared to both revenue and operating profit (EBITDA).

Delays in signing a couple of larger future European Space Agency contracts and contract additions, among them GAINTEX, lead to DAC now expecting a revenue for the Fiscal year 2023 to be in the range of DKK 23 million, just below the lower end of the formerly announced expectation. Further, it is expected that DAC’s EBITDA for 2023 will be in the range of DKK 1 million.

For further information:

Danish Aerospace Company A/S:

Chairman of the Board of Directors Niels Heering
Mobil: +45 40 17 75 31
Email: nh@gorrissenfederspiel.com

Thomas A.E. Andersen, CEO
Mobil: +45 40 29 41 62
Email: ta@danishaerospace.com

Certified Adviser:

Baker Tilly Corporate Finance P/S
Poul Bundgaards Vej 1
DK-2500 Valby
Tlf.: +45 33 45 10 00
www.bakertilly.dk

About Danish Aerospace Company A/S:

Danish Aerospace Company (DAC) is a high-tech company operating in the area of advanced medical instrumentation and other engineering fields primarily within space applications. Our products are based on many years of specialized research and development. These consist of developing, integrating, and applying new as well as established medical technologies to the challenges of functioning and remaining reliable in space. These products and services bring the potential of space research and experience from space operations down to Earth for the benefit of all Mankind.

Danish Aerospace Company employs engineers and technicians who deliver full engineering, production and technical services for our customers. We have specialized in customer specific design, development, manufacturing, certification, maintenance, testing, and operations.

The company has developed five generations respiratory equipment for spaceflight, cycle ergometers for astronauts’ countermeasures, adapted several commercial medical equipment for spaceflight and has participated in the development of the minus eighty-degree Celsius freezers.

The Company’s quality system is certified in obligation to BS EN ISO 9001:2015, BS EN 9100:2018 technically equivalent to AS9100D that are the acknowledged standard in the area.

Note: This is a translation of the corresponding Company Announcement in Danish. In case of discrepancies between the Danish wording and the English translation, the Danish wording prevails.

www.DanishAerospace.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Participation notification by DME Advisors and DME Capital Management21.2.2024 08:30:00 CET | Press release

Brussels, February 21, 2024, 08:30 CET - Regulated information In line with Belgian transparency legislation (Law of May 2, 2007), DME Advisors and DME Capital Management recently sent to Solvay the following transparency notifications indicating that they crossed the threshold of 3%. Here is a summary of the moves: Date on which the threshold was crossedDate on which Solvay received the notificationDME Advisors LPDME Capital Management LPTotalJanuary 8, 2024February 16, 20242.88%0.12%3.01%February 12, 2024February 19, 20243.00%0.12%3.12% The most recent notification, dated February 19, 2024, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotified by: A parent undertaking or a controlling personDate on which the threshold is crossed: February 12, 2024Threshold of direct voting rights crossed: 3% upwardsDenominator: 105,876,416 Full chain of controlled undertakings through which the holding is effectively hel

Sanoma Corporation - Managers' Transactions21.2.2024 08:15:00 CET | Press release

Sanoma Corporation, Managers’ Transactions, 21 February 2024 at 9:15 EET Sanoma Corporation - Managers' Transactions ___________________________________________ Person subject to the notification requirement Name: Holding Manutas Oy Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Anna Herlin Position: Member of the Board Issuer: Sanoma Oyj LEI: 743700XJC24THUPK0S03 Notification type: INITIAL NOTIFICATION Reference number: 52987/5/6 ____________________________________________ Transaction date: 2024-02-20 Venue: AQEU Instrument type: SHARE ISIN: FI0009007694 Nature of transaction: ACQUISITION Transaction details (1): Volume: 350 Unit price: 6.86 EUR (2): Volume: 3 Unit price: 6.87 EUR (3): Volume: 64 Unit price: 6.89 EUR (4): Volume: 88 Unit price: 6.93 EUR (5): Volume: 1 Unit price: 6.94 EUR (6): Volume: 350 Unit price: 6.99 EUR Aggregated transactions (6): Volume: 856 Volume weighted average price: 6.92272 EUR ___

CASH FLOW STRENGTHENED AND PROFITABILITY IMPROVED IN THE LAST QUARTER OF THE YEAR21.2.2024 08:15:00 CET | Press release

ROBIT PLC PRESS RELEASE 21 FEBRUARY 2024 AT 9.15 EET CASH FLOW STRENGTHENED AND PROFITABILITY IMPROVED IN THE LAST QUARTER OF THE YEAR Market demand weakened during 2023, which affected the construction industry in Europe and Asia in particular. Customer demand in the mining industry remained at a good level during the year, but the high stock levels of customers and distributors, and de-stocking, weakened Robit’s sales also in the mining industry. Robit’s net sales for 2023 declined by 17.0 percent to EUR 92.9 million (112.0). In constant currencies, the decline was 13.7 percent. A significant reason for the decreased sales was the closure of the Russian business, which had an 8.3 percent impact on the declined net sales. The company’s full-year EBITDA decreased from the 2022 level totaling EUR 5.0 million (8.9). Profitability was weak, especially in the early part of the year, but the company managed to improve it with the help of the austerity measures implemented during the year. I

Bavarian Nordic delivered record financial results in 202321.2.2024 08:13:33 CET | Press release

Preliminary 2023 results exceed the latest guidance and represent the best-ever financial result in the Company’s history driven by extraordinary growth in travel health and a surge in smallpox/mpox vaccine sales.2024 revenue of DKK 5,000-5,300 million and EBITDA of DKK 1,100-1,350 million expected.Focused R&D efforts to drive sustainable value creation within infectious diseases; discontinuing immuno-oncology projects.The Company will host three capital markets days during February. COPENHAGEN, Denmark, February 21, 2024 – Bavarian Nordic A/S (OMX: BAVA) today reports preliminary, unaudited financial results for 2023 and financial guidance for 2024. Furthermore, the Company provides an update on its R&D priorities. The preliminary revenue in 2023 was DKK 7,062 million compared to DKK 3,151 million in 2022, thus exceeding the annual guidance of DKK 6,900 million. The improved revenue was driven by the Public Preparedness segment due to a surge in sales of smallpox/mpox vaccines followi

Bavarian Nordic leverede rekordresultat i 202321.2.2024 08:13:33 CET | pressemeddelelse

De foreløbige resultater for 2023 overstiger de seneste forventninger og udgør selskabets bedste økonomiske resultater nogensinde, hvilket er en følge af ekstraordinær vækst inden for rejsevacciner og en stigning i salget af koppe-/mpoxvacciner.I 2024 forventes en omsætning på DKK 5.000-5.300 mio. og EBITDA på DKK 1.100-1.350 mio.Fokuserede aktiviteter inden for forskning og udvikling skal drive langsigtet værdiskabelse; selskabet ophører udviklingen inden for immunonkologi.Selskabet afholder tre kapitalmarkedsdage i slutningen af februar. KØBENHAVN, Danmark, 21. februar 2024 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag foreløbige, ureviderede finansielle resultater for 2023 samt forventninger til 2024. Desuden opdaterer selskabet på dets prioriteter inden for forskning og udvikling. Den foreløbige omsætning i 2023 var DKK 7.062 mio. sammenlignet med DKK 3.151 mio. i 2022 og oversteg dermed forventningerne til året om en omsætning på DKK 6.900 mio. Den forbedrede omsætning v

HiddenA line styled icon from Orion Icon Library.Eye